Recognition and Management of Complications During Moderate and Deep Sedation. Part 2: Cardiovascular Considerations

Daniel E. Becker, DDS* and Daniel A. Haas, DDS, PhD, FRCD(C)†

*Associate Director of Education, General Dental Practice Residency, Miami Valley Hospital, Dayton, Ohio, and †Associate Dean, Clinical Sciences, Professor and Head of Dental Anaesthesia Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada

The risk for cardiovascular complications while providing any level of sedation or general anesthesia is greatest when caring for patients already medically compromised. It is reassuring that significant untoward events can generally be prevented by careful preoperative assessment, along with attentive intraoperative monitoring and support. Nevertheless, providers must be prepared to manage untoward events should they arise. This continuing education article will review cardiovascular complications and address their appropriate management.

Key Words: Medical emergencies; Sedation; Anesthesia; Complications.

Complications attributed to moderate and deep levels of sedation are more often associated with respiratory compromise and have been reviewed in a previous continuing education article in this journal.1 Sedation, and general anesthesia for that matter, have minimal influence on overall cardiovascular function in reasonably healthy patients. In fact, cardiovascular complications may be even more likely during dental procedures using local anesthesia alone than when sedation is provided. However, respiratory compromise, excessive drug dosages, or inadequate anesthesia may trigger cardiovascular events, and the well-informed provider should be familiar with their recognition and management.

ABNORMALITIES IN ARTERIAL BLOOD PRESSURE

Neurocardiogenic (Vasovagal) Syncope

Syncope is a transient loss of consciousness due to reduced cerebral blood flow. It may occur unexpectedly but is often preceded by such signs and symptoms as pallor, lightheadedness, diaphoresis, and nausea. As brain tissues are deprived of oxygen, a brief period (ie, a few seconds) of convulsive motor activity is not unusual during a syncopal episode, especially if the patient remains in an upright posture. This event is frequently confused as a primary seizure event. Although syncope may be the result of a cardiac arrhythmia, in dental practice it is most often the result of what is commonly referred to as a vasovagal event. Vasovagal syncope is associated with an eventual loss of sympathetic tone (vasodilatation) and increased parasympathetic activity (bradycardia and gastrointestinal stimulation). The term neurocardiogenic syncope is used to encompass both vasovagal syncope and vasodepressor syncope in which only loss of sympathetic tone occurs.2 In either event, the syncopal episode is triggered by painful or stressful events not uncommon during dental procedures.

The pathogenesis of vasovagal syncope commences with increased peripheral sympathetic activity and venous pooling. A decline in venous return leads to forceful myocardial contractions of the left ventricle. This in turn activates myocardial mechanoreceptors and vagal afferent nerve fibers that inhibit sympathetic activity and increase parasympathetic activity. These events culminate in bradycardia, vasodilation, and the decline in blood pressure responsible for loss of consciousness.2 Indeed, it is not unusual for a syncopal episode to be preceded by a brief period of forceful pounding of the heart and tachycardia, which contribute
to the subsequent neural reflexes leading to the vasovagal event.

The depth and duration of unconsciousness during vasovagal syncope are highly variable. In some cases, vagal influences are severe enough to induce transient periods of asystole that persist for 30–40 seconds. Its management should be well understood by all dentists, whether or not sedation is being administered. This consists of carrying out the primary assessment and management of airway, breathing, and circulation while positioning the patient supine with legs elevated. Regardless of the cause or severity, vasovagal events will generally subside during the time primary measures for assessment and airway support are instituted. Subsequently, attention must be directed toward abnormalities in blood pressure and heart rate that may or may not require pharmacologic intervention. Syncope that does not resolve spontaneously or with minor intervention is unlikely vasovagal in mechanism, and other causes, such as cardiac arrhythmia, stroke, and drug overdose, should be explored.

**Hypotension**

Episodes of hypotension in clinical practice are most commonly associated with vasovagal events and are generally transient, but they may become prolonged in the presence of central nervous system depressants. The same can be said for postural (orthostatic) hypotension, which normally subsides with proper repositioning of the patient. The blood pressure required to perfuse tissues adequately varies from patient to patient and is influenced by their medical status and posture at the time of assessment.

A significant decline in blood pressure from baseline should alert the clinician, but hypotension cannot be established on precise numerical values alone. Evaluation of tissue perfusion is the more significant component of cardiovascular assessment. Color changes in the skin and mucosa and the rate of capillary refill subsequent to squeezing of the nail beds can be used as a guide for assessing perfusion of peripheral tissues. The adequacy of perfusion within the central nervous system can be estimated by the patient’s response to verbal and painful stimuli in the conscious patient or by pupillary reflex when they are unconscious or heavily sedated. If blood pressure has declined and perfusion is considered inadequate, the clinician may elect to increase blood pressure. To do this appropriately, several physiologic principles must be considered.

Blood pressure fluctuates continuously due to the cyclic nature of the pumping action of the heart. The highest pressure is produced by ventricular contraction (systole) and is designated systolic blood pressure. The lowest pressure occurs during ventricular relaxation (diastole) and is therefore designated as diastolic blood pressure. This is the result of arterial resistance. Mean arterial pressure is the time-weighted average of the blood pressure throughout the cardiac cycle and is an indication of adequacy or inadequacy of perfusion.

One must avoid excessive elevation of arterial resistance and diastolic pressure, because it can produce undue strain on the heart. For the heart to eject a stroke volume, the left ventricle must generate a pressure that exceeds peripheral resistance. In other words, ventricular pressure must exceed diastolic pressure. This resistance to ventricular ejection is called *afterload*, and for a patient with heart disease, elevated diastolic pressure not only stresses the heart but may also hinder ejection of an adequate stroke volume. On the other hand, coronary artery blood flow occurs during diastole when the heart muscle relaxes, so a reasonable diastolic blood pressure must be present for the heart to be nourished before the next systolic contraction occurs. However, diastolic blood pressures of 30 mm Hg are generally adequate for this purpose for most adults. In the primary care setting, systolic blood pressure is the target of monitoring and interventions.

Systolic blood pressure is primarily a function of cardiac output, which is calculated as ventricular rate multiplied by the stroke volume. Of these 2 factors, stroke volume is most significant in adults because it provides the “surge” that creates the systolic pressure. Except for small children and infants, the heart rate acts merely as a “compensator” for changes in stroke volume. For example, slow rates are common in well-trained athletes, but rapid rates are required to sustain adequate cardiac output for patients having low stroke volumes due to heart failure. Therefore, when managing a hypotensive patient, our primary goal is to improve stroke volume.

Stroke volume can be increased in 2 manners: (a) by improving myocardial contractility, which is augmented by sympathetic stimulation of beta-1 receptors, and (b) by increasing venous return to the heart (preload). According to the Frank-Starling law, preload is directly related to stroke volume, but there is a limit to this relationship. If a critical preload volume is exceeded, congestion occurs. This volume is lower for patients having compromised cardiac function and should be considered when positioning a patient. Although in the past the Trendelenburg position had been cited as the preferred position for patients experiencing medical emergencies, it may allow excessive venous return (increase preload) and compromise patients with cardiac or respiratory disease. In fact, it appears this position offers few advantages. Thus,
the more appropriate position when managing most medical complications in sedated patients or those who are unresponsive is to have the patient supine with the legs elevated slightly. Improving venous return will also increase heart rate according to the Bainbridge reflex. When the right atrium is stretched by venous return, it is sensed by receptors in the area of the sinoatrial node, leading to an increase in heart rate to better accommodate the returning volume.

Figure 1 summarizes and illustrates the influences of various parameters on arterial blood pressure.

In general, a systolic blood pressure of 90 mm Hg should sustain mean arterial pressure sufficiently to perfuse tissues in the recumbent patient. A pressure lower than this combined with evidence of inadequate perfusion requires intervention. This can be accomplished in the following manners: (a) improve venous return by positioning the patient, administering intravenous fluid, or administering drugs that provide vasoconstriction to increase venous pressure and preload; (b) increase myocardial contractility (inotropy) using drugs that activate beta-1 receptors on myocardial cells, providing a positive inotropic influence.

If repositioning of the patient to improve venous return, such as described above, fails to improve the situation, subsequent intervention should proceed in the following manner. If an intravenous line is in place or can be established readily, 250–500 mL of physiologic solution, such as normal saline, should be infused rapidly unless congestive heart failure is suspected. Generally, this will increase preload sufficiently to improve stroke volume and raise systolic pressure. When this maneuver cannot be accomplished or proves unsuccessful, the patient’s heart rate should guide further treatment. If bradycardia is present, that is, <60 beats/min, administer intravenous atropine until the rate is within normal limits. This is accomplished in 0.5-mg increments. Suggested dosages for medications addressed throughout this article are summarized in Table 2. If the rate is >60 beats/min and pressure remains low, increasing the rate further may do little to improve systolic pressure. As heart rate increases, the time allocated for diastolic filling and each subsequent stroke volume will decline.

Although several adrenergic drugs may be acceptable to manage hypotension, ephedrine is often an ideal choice for several reasons. Hypotension encountered during dental practice is usually attributed to either vasovagal episodes or the use of sedatives and anesthetics that depress sympathetic outflow to the cardiovascular system. (In Advanced Cardiac Life Support courses, however, hypotension is generally cardiogenic and requires more powerful inotropics, such as dopamine and epinephrine.) In either case, ephedrine specifically counters these influences indirectly by stimulating norepinephrine release from sympathetic nerve endings. Also, ephedrine acts directly on alpha- and beta-adrenergic receptors, leading to vasoconstriction and increased rate and contractility of the myocardium. Ephedrine constricts veins to a greater extent than arteries, which enables it to increase preload more than afterload. This results in less of an increase in myocardial oxygen demand compared with other vasoressors. Finally, unlike epinephrine and other catecholamines having brief durations of action, that is, 5–10 minutes, the cardiovascular effects of ephedrine continue for 60–90 minutes. Ephedrine can be administered intravenously in 5- to 10-mg increments or 25 mg by sublingual or intramuscular injection. Exceeding a total dose of 50 mg is not recommended.

When it is secondary to hypovolemia, hypotension can be accompanied by tachycardia, so the cardiotonic effects of ephedrine may be undesirable. This situation occurs most often when hypotension is the result of spinal anesthesia, hypovolemia, or dehydration and is unlikely in the dental setting, where hypotension is generally either vagal induced or attributed to drugs that depress the central nervous system. However, patients who have been without oral food and fluids for extended periods may present with a relative hypovolemia secondary to dehydration.

Phenylephrine is an alpha-adrenergic agonist that is useful for treating hypotension when tachycardia is
Phenylephrine is typically administered by continuous intravenous infusion or in 0.1-mg intravenous increments. Its use should be accompanied by adequate fluid administration to ensure that hypovolemia is not present. The use of phenylephrine is best reserved for those with training in deep sedation and general anesthesia. An algorithm approach for managing hypotension is presented in Figure 2.

**Hypertension**

Sudden elevations in blood pressure are not that uncommon in dental practice, regardless of whether sedation is being provided. Precise blood pressures of significance are not defined, but sudden elevations to systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg are generally regarded as an acute hypertensive episode, keeping in mind that this suggestion fails to consider the patient’s baseline readings. In patients with chronic hypertension, autoregulation of cerebral blood flow is reset to a higher level, and abruptly lowering pressure can lead to cerebral ischemia. This is particularly true for geriatric patients.

A hypertensive episode is generally regarded as urgent when the patient remains asymptomatic and rarely requires treatment other than a “time out” to calm down. These episodes are most likely attributed to waning local anesthesia, a need to use the restroom, or restlessness during lengthy procedures. Gallagher summarized this issue vividly in an article for physicians in the emergency department. “The most sensible approach to the patient in the emergency department found to have very high blood pressure, without evidence of acute end organ damage, is referral for outpatient management of serious disease that needs to be treated, not urgently, but for life. Focusing on the height of the column of mercury in the sphygmomanometer confers no demonstrable benefit on the patient and risks doing harm.”

Simply stated, patients without acute end-organ symptoms should not receive antihypertensive agents in the office, and they may be safely referred to their primary physician for follow up within several days.

*Hypertensive emergency* and *crisis* are terms used to describe an acute hypertensive episode accompanied by symptoms of end-organ damage. The event includes chest pain, headache, or visual disturbances. In this case, emergency medical service transport should be arranged immediately. While awaiting emergency medical service transport arrival, any decision to lower the blood pressure is based on the judgment and experience of the provider. If treatment is elected, the goal is to lower the blood pressure by ~20% within 30–60 minutes. However, if signs or symptoms are consistent with stroke, it is wise to avoid any intervention and continue to support the patient while awaiting emergency medical service transport arrival. Clinically, one cannot ascertain if injury is hemorrhagic or infarcted, and ischemic brain may be critically dependent on collateral perfusion pressure. Any reduction in blood pressure could prove catastrophic. In this scenario, only extremely high systolic blood pressure (≥220 mm Hg) or diastolic blood pressure (≥120 mm Hg) should even be considered for treatment.

A variety of drugs and drug classes are suggested for management of hypertensive emergencies. However, nitroglycerin and labetalol are consistently mentioned and are adequate for office preparedness. Nitroglycerin is a vasodilator that acts predominantly on the venous system, decreasing venous return to the atria and ventricles. At conventional doses, nitroglycerin has little effect on arterial resistance and lowers blood pressure by reducing preload and subsequent cardiac output. This action may be undesirable in patients with impaired cerebral perfusion and should not be used if stroke is suspected. However, it is ideal for those with cardiac symptoms. Nitroglycerin may be administered either sublingually or intravenously, but the former route is most appropriate in the office setting. A single 0.4-mg tablet can be placed sublingually and repeated every 5 minutes while checking blood pressure response before each subsequent dose. Caution is advised when administering more than 1 dose because...
the incidence of headache may become problematic. In any case, no more than 3 doses should be considered.

Labetalol (Trandate and Normodyne) is a selective alpha-1-blocker and nonselective beta blocker with a ratio of alpha/beta blockade of 1 : 5. Labetalol lowers blood pressure by blockade of the alpha-1 receptors in vascular smooth muscle and the beta-1 receptors in the heart. Because of the simultaneous beta receptor blockade, the usual reflex tachycardia associated with other vasodilators does not occur. It can be administered in 5- to 20-mg increments, depending on the response to the initial dose, while checking blood pressure before each subsequent dose. Patients under sedation or general anesthesia may be more susceptible to the lower dose range. The expected onset of action of intravenous labetalol is 5 minutes. The maximum dose is 0.5 mg/kg or 300 mg, but this amount will rarely be required. When administered in this manner, labetalol is safe with minimal adverse reactions. Like all nonselective beta blockers, labetalol is contraindicated in patients with chronic obstructive pulmonary disease or asthma. Blockade of beta-2 receptors on bronchial smooth muscle may result in bronchoconstriction. Labetalol should be used only by those with advanced training and only when continuous electrocardiographic (ECG) monitoring and minute-by-minute blood pressure recording are in place.

Any drug that lowers blood pressure increases a patient’s risk for orthostatic (postural) hypotension. Due to its longer duration of action, labetalol carries a greater risk than nitroglycerin and patients should be ambulated with great caution. This concern is unlikely in the office setting because any indication for using labetalol is likely accompanied by the need for emergency medical service transport. An algorithm approach for managing acute hypertensive events is presented in Figure 3.

**ABNORMALITIES IN THE HEART**

**Cardiac Dysrhythmias**

Most dentists have witnessed a patient complaining of cardiac palpitations after administration of a local anesthetic with epinephrine or during forceful procedures. Frequently this is the result of benign dysrhythmias, such as extrasystoles (premature contractions), but they pass unnoticed because continuous ECG monitoring is usually not in place. Published guidelines for patient monitoring during sedation are consistent in requiring continuous assessment of oxygenation by pulse oximetry. This also provides continuous monitoring of pulse rate but not the specific rhythm, and guidelines for the use of ECG monitoring are less consistent. While stating that moderate and even deep sedation have minimal impact on cardiovascular function, the American Society of Anesthesiologists guidelines nevertheless require ECG monitoring for even moderate levels of sedation. This has no evidence-based scientific basis, but from the society’s perspective, it is understandable. All monitoring systems used by anesthesiologists include electrocardiography, and any case scheduled initially for sedation may require instant conversion to a full general anesthetic. However, this requirement may be excessive for the dentist providing only moderate sedation, and guidelines published by the American Dental Association are more practical for the average moderate sedation–trained dentist. These guidelines do, however, require continuous ECG monitoring for deep sedation and general anesthesia, but its use for moderate sedation is suggested only for patients having significant cardiovascular disease. This would include patients who have known rhythm disturbances, including those managed with implanted pacemakers.

Legal controversies aside, there is an intangible reassurance provided by an ECG monitor that adds to that provided by periodic measurement of blood pressure and continuous pulse oximetry. This of course presumes the operator understands and can interpret electrocardiograms and is comfortable witnessing occasional benign dysrhythmias and the subtle mechanical nuances all monitors present during routine use. The precise interpretation of a particular dysrhythmia
Supraventricular Bradydysrhythmias

Bradycardia is defined as a heart rate of <60 beats/min, but symptoms normally do not arise unless the rate falls to <50 beats/min. Supraventricular bradydysrhythmias may be sinus or junctional in origin, or they may be caused by various degrees of atrioventricular block. In most cases, these events are vagally induced, but central nervous system depressants are potential culprits and may potentiate vagal activity when present. Hypoxemia can also be a common cause, and efforts should be made to investigate and correct this possibility. The precise diagnosis of bradyarrhythmia is not as important as evidence of hemodynamic compromise (hypotension) or ventricular ectopy (premature ventricular contraction [PVC]) due to ventricular escape. When either of these events is present, the bradycardia should be treated with atropine, as previously explained in the discussion of hypotension in this article.

If a bradycardia does not respond after 2 doses of atropine, a second or third degree atrioventricular block should be investigated. Second-degree type II and third-degree blocks are located below the atrioventricular node, where there is no parasympathetic innervation. Atropine is seldom effective for infranodal block, and these cases require EMS transport for eventual pacemaker insertion. If hypotension remains significant while awaiting EMS transport, the recommended treatment is epinephrine by continuous infusion titrated from 2–10 μg/min. This can be accomplished by adding 1 mL of 1:1000 epinephrine to a 500-mL bag of normal saline or 5% dextrose, which provides a concentration of 2 μg/mL. Titration with an infusion pump should commence at 1 mL/min with incremental increases guided by blood pressure and heart rate. An epinephrine infusion should be used only by those with advanced training and when continuous ECG monitoring and minute-by-minute blood pressure recording are in place.

Sinus and Supraventricular Tachydysrhythmias

Tachycardia is defined as a heart rate >100 beats/min, but usually it is not until rates exceed 150 that patients become symptomatic. Transient episodes of tachycardia are triggered most often by pain, stress, and vasoconstrictors included in local anesthetic solutions. It may be an indication that the sedation being administered is not sufficient to manage the patient’s fear. It is important to establish whether the tachycardia is secondary to pain, stress, or vasoconstrictors or whether the tachycardia is truly cardiogenic, which may lead to hypotension or myocardial ischemia. This tachycardia is almost always controlled by the sinoatrial node and is called sinus tachycardia; a P wave precedes each QRS complex. Sinus tachycardia can also be an initial reflex response to hypoxia or hypotension, and these should be considered before further treatment. Once these possibilities have been attended, persistent tachycardia may cause the patient to complain of palpitations. In this case, intravenous fluids should be administered to support blood pressure in the event the rapid heart rate is attempting to sustain the blood pressure in a hypovolemic patient. If the episode continues, a selective beta-1 receptor antagonist, such as esmolol (Brevibloc), can be administered. Due to its relatively brief duration of action (T1/2 ~9 minutes), esmolol is generally administered as a bolus of 0.5 mg/kg over 2 minutes followed by a continuous intravenous infusion. For office use, we suggest it be titrated intravenously in 20-mg increments every 2–3 minutes until the heart rate declines to an appropriate level. There is no maximum dose published for esmolol, but 80–100 mg is a reasonable limit before determining it is ineffective. If the tachycardia does not respond to this dosage or recurs after the effects of esmolol have waned, EMS transport should be considered. Compared with nonselective beta blockers, such as labetalol, esmolol is less likely to produce bronchospasm, but it must nevertheless be used with caution in patients with chronic obstructive pulmonary disease or asthma. Esmolol should be used only by those with advanced training and only when continuous ECG monitoring and minute-by-minute blood pressure recording are in place.

Sinus and supraventricular tachydysrhythmias are distinguished from ventricular dysrhythmias by narrow QRS complexes. If P waves are not evident preceding the QRS, the rhythm is not sinus in origin and is described as supraventricular. These dysrhythmias include atrial flutter, atrial fibrillation, and supraventricular tachycardia. It must be emphasized that atrial flutter and fibrillation are fairly common chronic conditions that are usually well tolerated due to medications that control ventricular rate. They introduce concern only when ventricular rate accelerates or they present as a new onset.

In contrast to atrial flutter and fibrillation, supraventricular tachycardia is not a chronic condition,
although a patient may have a history of paroxysmal episodes. An onset of supraventricular tachycardia is always a concern. It is generally more rapid, producing heart rates >150 beats/min, and can be distinguished from the others by its regular ventricular rhythm (ie, regular R to R intervals). A precise diagnosis can be challenging, but the important feature determining a need for treatment is hemodynamic instability, that is, hypotension. Although adenosine is regarded as the drug of choice for confirmed supraventricular tachycardia, a beta blocker, such as esmolol, is also an option. Furthermore, esmolol is also an option in treating symptomatic atrial flutter and fibrillation. For this reason, esmolol is an acceptable choice for managing any of the atrial tachyarrhythmias. Compared with sinus tachycardias, any of the supraventricular dysrhythmias that become symptomatic are a far greater concern, and EMS transport should be arranged as treatment is rendered.

**Extrasystoles (Premature Contractions)**

Extrasystoles are ectopic impulses that occur in addition to the underlying rhythm and occur in most individuals. By convention, the term contraction is applied to these extra impulses, although a true mechanical contraction may not always occur. The source of these ectopic impulses can be anywhere throughout the atria and ventricles: premature atrial contractions, premature junctional contractions, or PVCs. In general, they are all relatively benign rhythms, and any new onset may reflect some sort of stress response that should be addressed.

PVCs are distinguished from other extrasystoles by their bizarre and widened QRS complex. They are generally benign, but when they occur with considerable frequency, they do have a greater potential for complications than other extrasystoles. They may produce hemodynamic instability or lead to lethal dysrhythmias, such as ventricular tachycardia and fibrillation. The Lown criteria are used to classify PVCs according to their frequencies and patterns (Table 1). After myocardial infarction, Lown classes 3–5 have been found to be associated with a greater risk for conversion to lethal dysrhythmias, but this correlation has not been established for other patients. Nevertheless, a reasonable caveat is that treatment is unlikely necessary for PVCs having a uniform appearance, regardless of frequency, unless the patient becomes hypotensive. For classes 3–5, treatment and EMS transport are reasonable decisions.

There are many antidysrhythmic drugs advocated for treating patients with PVCs, but lidocaine is the safest and least sophisticated to administer. It can be administered as a single 0.5- to 1-mg/kg dose and repeated every 5 minutes up to 3 mg/kg. Its influence will generally last 15–20 minutes, after which a continuous infusion of 1–2 mg/min is required if the condition persists. However, when a patient remains symptomatic after 1 or 2 incremental doses or the condition recurs after its effects have waned, EMS transport should be arranged.

Before electing to use lidocaine for PVCs, it is important to confirm that the underlying rhythm is not a bradycardia, in which the PVCs represent efforts at ventricular escape. In this case, atropine should be administered to increase the underlying heart rate. The ventricular escape beats will then hopefully subside.

**Ventricular Tachycardia**

Unlike ventricular fibrillation, ventricular tachycardia may not be accompanied by cardiac arrest. It can be distinguished from atrial tachydysrhythmias by wide QRS complexes and the absence of atrial waveforms. It is not uncommon for patients to remain relatively stable while experiencing this dysrhythmia, but it can deteriorate rapidly to cardiac arrest. EMS transport should be summoned immediately. Current advanced cardiovascular life support guidelines suggest procainamide, amiodarone, and sotalol as preferred agents, but lidocaine is still regarded as an acceptable alternative and can be administered in the identical regimen addressed for management of PVCs. If the patient develops chest pain or becomes hypotensive, synchronized cardioversion is recommended if available. The office team should prepare for cardiac arrest, should it occur. Figure 4 provides an algorithm approach for managing atrial and ventricular tachydysrhythmias.

**Chest Pain: Angina/Myocardial Infarction**

When any of the previously discussed complications become extremely severe, they can either strain the

---

**Table 1. Lown Classification of Premature Ventricular Contractions**

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
</tr>
<tr>
<td>1</td>
<td>&lt;30/hr</td>
</tr>
<tr>
<td>2</td>
<td>≥30/hr</td>
</tr>
<tr>
<td>3</td>
<td>Multiform (or multifocal)</td>
</tr>
<tr>
<td>4A</td>
<td>2 consecutive (couplet)</td>
</tr>
<tr>
<td>4B</td>
<td>≥3 consecutive (run of ventricular tachycardia)</td>
</tr>
<tr>
<td>5</td>
<td>R-on-T phenomenon</td>
</tr>
</tbody>
</table>

*Adapted from Yeally and Delbridge.*
heart or compromise coronary perfusion to the point that the patient may experience an episode of angina pectoris. However, this form of chest pain is most likely to occur if the patient has preexisting coronary artery disease. The event may represent an episode of stable angina or a more serious event labeled acute coronary syndrome. To understand this difference, a basic understanding of the pathogenesis of coronary artery disease must be appreciated.

The fundamental defect in coronary artery disease is stenosis, or narrowing of the lumen of coronary arteries due to atherosclerosis. The condition is not acutely life threatening so long as the lesion remains stable and does not rupture. The patient may experience chest pain if cardiac stress suddenly increases because coronary “supply” is outweighed by myocardial oxygen demand. These episodes of chest pain are regarded as “stable angina” and can be precipitated by the stress of dental treatment. The angina will dissipate when cardiac stress is reduced by calming the patient and perhaps administering a dose of nitroglycerin.

A more serious consequence occurs when atherosclerotic lesions become unstable and rupture, producing the so-called “acute coronary syndrome.” In this case, coronary perfusion becomes even further compromised. Added to the preexisting stenosis, debris

### Table 2. Relevant Data for Emergency Drugs*

<table>
<thead>
<tr>
<th>Indication/Drugs</th>
<th>Action</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradycardia/hypotension</td>
<td>Cholinergic (muscarinic) receptor antagonist</td>
<td>IV: 0.5 mg q 2–3 min (3 mg total)</td>
</tr>
<tr>
<td>Atropine (1.0 mg/mL)</td>
<td></td>
<td>IM/SLI: 0.5 mg q 5–10 min (3 mg total)</td>
</tr>
<tr>
<td>Ephedrine (50 mg/mL)</td>
<td>Releases norepinephrine; alpha/beta receptor agonist</td>
<td>IV: dilute 1 mL in 5 mL = 10 mg/mL; then 10 mg q 2–3 min (50 mg total)</td>
</tr>
<tr>
<td>Phenylephrine (10 mg/mL)‡</td>
<td>Selective alpha agonist</td>
<td>IV: double dilute 1 mL in 10 mL = 1 mg/mL; then discard 9 mL and dilute remaining 1 mL in 0.1 mg/mL; administer 0.1-mg increments q 2–3 min (0.5 mg total) or by infusion</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Venodilator</td>
<td>Sublingual: 1 tablet q 5 min × 3</td>
</tr>
<tr>
<td>Nitroglycerin (0.3- or 0.4-mg tablet or 0.4-mg spray)</td>
<td></td>
<td>IV: 5–20 mg q 5 min (300 mg total)</td>
</tr>
<tr>
<td>Labetalol (5 mg/mL)‡</td>
<td>Alpha/beta receptor antagonist</td>
<td>See bradycardia/hypotension above.</td>
</tr>
<tr>
<td>AV blocks</td>
<td>Cholinergic (muscarinic) receptor antagonist</td>
<td>IV infusion: add 1 mg (1 mL) to 500 mL normal saline or 5% dextrose in water = 2 µg/mL; start titration at 1 mL/min</td>
</tr>
<tr>
<td>Atropine (1.0 mg/mL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epinephrine (1 mg/mL)‡</td>
<td>Alpha/beta agonists</td>
<td></td>
</tr>
<tr>
<td>Tachycardias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esmolol (10 mg/mL)‡</td>
<td>Beta-1 receptor antagonist</td>
<td>IV: 20 mg q 2–3 min (0.5 mg/kg bolus if severe); repeat as needed</td>
</tr>
<tr>
<td>Lidocaine (2%) 20 mg/mL, 5-mL prefilled syringe‡</td>
<td>Sodium channel blocker</td>
<td>IV: 1.0–1.5 mg/kg q 3–5 min (3 mg/kg total)</td>
</tr>
<tr>
<td>Angina/myocardial infarction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin (0.3- or 0.4-mg tablet or 0.4-mg spray)</td>
<td>Venodilator</td>
<td>Sublingual: 1 tablet q 5 min × 3 if needed</td>
</tr>
<tr>
<td>Morphine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>Antiplatelet agent</td>
<td>Chew and swallow: 1 full-strength (325 mg) tablet or 4 baby-strength (81 mg) tablets</td>
</tr>
</tbody>
</table>

* This table summarizes emergency drugs addressed in this article.
‡ Indicates medications the authors suggest be used only by those with advanced formal training in deep sedation and general anesthesia and that require minute-by-minute blood pressure and electrocardiographic monitoring. Advanced providers may also consider additional agents suggested in advanced cardiovascular life support guidelines.

IV indicates intravenous; IM, intramuscular; SLI, sublingual injection; and AV, atrioventricular.
The actual criteria for need and timing for activation of EMS transport are not well established. The package inserts for nitroglycerin formulations instruct patients with angina pectoris to access EMS transport when 3 doses of nitroglycerin over 15–20 minutes fail to relieve symptoms. Pollack and Braunwald24 have suggested that EMS transport is indicated after administration of 3 doses of nitroglycerin over a 15- to 20-minute period for stable angina but only 1 dose if angina is deemed unstable. Current American Heart Association guidelines25 address only suspected acute coronary syndrome (unstable angina or myocardial infarction) and encourage immediate EMS transport. They do not address stable angina. However, it may be impossible for the dentist to ascertain if the condition represents a stable or unstable event, and personal judgment must be used regarding subsequent action. For a patient with
preexisting coronary disease, chest pain provoked by a particularly stressful intervention may well represent a typical episode of stable angina. In this case, the patient will respond nicely after a primary assessment or a single dose of nitroglycerin and could very well be sent home after the dental treatment is completed. In contrast, patients having no prior history of angina or who require more than their usual dose to relieve symptoms should be transported to an emergency department for further evaluation. In all cases, it is professionally courteous to inform the patient’s primary physician when possible.

With activation of EMS transport, the decision has been made that the condition is possibly an acute coronary syndrome, and aspirin (300 mg) should be administered. This is accomplished ideally by chewing and swallowing either 3 or 4 chewable, flavored baby aspirins (81 mg each) or a regular 325-mg tablet. Platelet aggregation is a key factor during coronary thrombosis, and the maximum antiplatelet influence of aspirin is achieved within 1 hour of administration. Nitroglycerin can be continued every 5 minutes, provided systolic pressure is at least 90 mm Hg and the heart rate is within normal limits.

If pain is severe and persistent, an opioid (narcotic) can be administered. Opioids not only relieve pain and anxiety but also reduce peripheral resistance (afterload) and venous capacitance (preload). This reduces myocardial oxygen demand, that is, a nitroglycerin-like effect. Although morphine is ideal and thus the conventional agent recommended, fentanyl and nalbuphine are acceptable alternatives. Opioids are more likely to produce hypotension if nitroglycerin has been administered, and the clinician should monitor blood pressure carefully and often. An opioid should be considered only if an intravenous infusion is in place and the clinician is familiar with its use. A suggested algorithm for management of chest pain is provided in Figure 5.

### Cardiac Arrest

Cardiac arrest is the absence of a pulse. In the office setting, the ECG status will most likely commence with ventricular tachycardia, which deteriorates to ventricular fibrillation. This can subsequently deteriorate further to asystole or pulseless electrical activity. Cardiac arrest is most often attributed to myocardial infarction but may also be triggered by other factors, such as sustained hypoxemia due to severe respiratory depression or airway obstruction.

Once primary assessment confirms cardiac arrest, EMS transport must be obtained immediately and the office team should commence cardiopulmonary resuscitation following the 2010 American Heart Association guidelines as instructed in all health care provider courses in basic life support. An exemplary office protocol is presented in Figure 6. Ventilations should be performed using a bag-valve-mask device (eg, Ambu-Bag) attached to a 100% oxygen source. Chest compressions must be rapid (100/min) with pauses after 30 compressions to allow for 2 adequate ventilations. There is little excuse for the entire office staff not being certified in basic life support at the health care provider level.
Figure 7. Abridged version of the advanced cardiovascular life support cardiac arrest algorithm. When cardiac arrest is determined, the emergency medical service (911) should be alerted and cardiopulmonary resuscitation commenced immediately as presented in Figure 6. The office team may then follow this abridged version of the 2010 American Heart Association cardiac arrest algorithm.\(^{19}\) Analysis of the time required for each step in this sequence will reveal that any decision regarding choice of antidysrhythmic drug will likely be unnecessary because the emergency medical service will have arrived.

*Lidocaine 1.5 mg/kg is alternative, but EMS should arrive at this time.*

**REFERENCES**


CONTINUING EDUCATION QUESTIONS

1. You have sedated a 62-year-old man with a history of hypertension managed with losartan (Cozaar) and hydrochlorothiazide. His preoperative blood pressure was 138/88 and 126/81 after sedation. Approximately 30 minutes into the procedure, your monitor records a pressure of 182/102, which you subsequently reconfirm. The patient is calm and asymptomatic. Which of the following is the most appropriate action?
   A. If signs of stroke develop, 20 mg of intravenous labetalol should be administered.
   B. 0.4 mg of nitroglycerin should be administered.
   C. The patient should be transported by emergency medical service for further evaluation.
   D. Treatment should be paused and possible causes (eg, inadequate local anesthesia) ruled out.

2. Which of the following is correct regarding tachycardias and ectopy?
   A. Supraventricular tachycardias always have a P wave before every QRS.
   B. Emergency medical service should be called for a patient experiencing any form of tachycardia.
   C. Drug administration is NOT required for a patient having uniform-appearing premature ventricular contractions at a rate of 1 or 2/min.
   D. Tachycardias with narrow QRS complexes are ventricular in origin and should be managed with 1 mg/kg lidocaine.

3. Your patient is a 57-year-old man with a history of coronary artery disease. His medications include metoprolol and nitroglycerin. He has not used the nitroglycerin in the previous 6 months. While an extraction is being attempted, he complains that the area is not numb and that he is experiencing chest pain. Which of the following is the most appropriate management for this patient?
   A. Nitroglycerin should be administered sublingually in a dose of 0.3 or 0.4 mg.
   B. Emergency medical service transport should be called.
   C. An automated external defibrillator should be applied to the patient.
   D. A 1-mg dose of epinephrine should be administered intravenously.

4. Your patient is a 24-year-old woman scheduled for a third molar extraction under sedation. She has a negative medical history other than Zoloft for panic disorder. After administration of local anesthetic, she loses consciousness. Your primary assessment reveals that she is breathing and has a pulse. Her oxygen saturation is 98%, blood pressure is 70/50, and pulse rate is 74. All of the following are appropriate for managing this situation EXCEPT:
   A. Administer or increase supplemental oxygen.
   B. Administer 0.5 mg of atropine intravenously, intramuscularly, or injected sublingually.
   C. Administer 10 mg of ephedrine intravenously or 25 mg intramuscularly or injected sublingually.
   D. Administer 250–500 mL intravenous fluid.